-

Dexcom to Host Investor Day on December 9, 2020

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business strategy, innovation efforts and long-term financial outlook.

Dexcom will host a live webcast of the event with no pre-registration required, enabling access for all interested stakeholders. The webcast can be accessed at dexcom2020investorday.com, or by navigating to the Dexcom Investor Relations website (https://investors.dexcom.com/) on the Events and Presentations page. A replay of the event will be available shortly after its conclusion.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom to Host Investor Day on December 9, 2020
Release Versions
English

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and...

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,...
Back to Newsroom